Soheilipur Kobra, Khazdair Mohammad Reza, Moezi Seyyed Ali, Mahmoudirad Gholamhossein
Faculty of Nursing and Midwifery, Birjand University of Medical Sciences, Birjand, Iran.
Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Avicenna J Phytomed. 2021 Sep-Oct;11(5):515-526. doi: 10.22038/AJP.2021.18077.
Coronary artery disease (CAD) is among the most prevalent diseases in the world, and its severity is usually assessed through coronary angiography (CA). Anxiety is the most prevalent problem before angiography. The aim of this study was to evaluate (saffron) and Kunth (lippia) extracts and saffron-lippia extract combination on anxiety among the candidates for CA.
This double-blind randomized placebo-controlled trial in four month was conducted on 120 angiography candidates in Valiasr hospital, Birjand, Iran. The random allocation was doing through block randomization to saffron, lippia, saffron-lippia, and placebo groups; four hours before angiography, participants in these groups respectively received a single dose of saffron extract capsule (40 mg), lippia extract capsule (40 mg), saffron-lippia extract capsule (20 mg saffron and 20 mg lippia), and lactulose capsule (40 mg). Participants' anxiety was assessed before, thirty minutes after, and three hours after the intervention via Spielberger State-Trait Anxiety Inventory.
The mean scores of state, trait, and total anxiety in the saffron group reduced significantly (p<0.05), while the mean scores in the other groups did not change significantly, except for the mean score of trait anxiety in the saffron-lippia group which decreased significantly (p=0.05). Therefore, after the intervention, the mean scores of state, trait, and total anxiety in the saffron group were significantly lower than the other groups (all, p<0.05).
This study suggests that the oral use of a single-dose of 40 mg saffron extract is effective in alleviating anxiety among the candidates for CA.
冠状动脉疾病（CAD）是世界上最常见的疾病之一，其严重程度通常通过冠状动脉造影（CA）来评估。焦虑是造影前最常见的问题。本研究的目的是评估藏红花提取物、光叶巴豆提取物以及藏红花 - 光叶巴豆提取物组合对冠状动脉造影候选者焦虑情绪的影响。
本双盲随机安慰剂对照试验历时四个月，在伊朗比尔詹德瓦利阿斯尔医院对120名冠状动脉造影候选者进行。通过区组随机化将其随机分配至藏红花组、光叶巴豆组、藏红花 - 光叶巴豆组和安慰剂组；在造影前4小时，这些组的参与者分别接受单剂量的藏红花提取物胶囊（40毫克）、光叶巴豆提取物胶囊（40毫克）、藏红花 - 光叶巴豆提取物胶囊（20毫克藏红花和20毫克光叶巴豆）和乳果糖胶囊（40毫克）。通过斯皮尔伯格状态 - 特质焦虑量表在干预前、干预后30分钟和3小时评估参与者的焦虑情况。
藏红花组的状态焦虑、特质焦虑和总焦虑平均得分显著降低（p<0.05），而其他组的平均得分没有显著变化，除了藏红花 - 光叶巴豆组的特质焦虑平均得分显著降低（p = 0.05）。因此，干预后，藏红花组的状态焦虑、特质焦虑和总焦虑平均得分显著低于其他组（均p<0.05）。
本研究表明，口服单剂量40毫克藏红花提取物可有效缓解冠状动脉造影候选者的焦虑情绪。
